Pembrolizumab in endometrial cancer: Where we stand now.

Aravantinou-Fatorou, Aikaterini; Andrikopoulou, Angeliki; Liontos, Michael; Fiste, Oraianthi; Georgakopoulou, Vasiliki E; Dimopoulos, Meletios-Athanasios; Gavriatopoulou, Maria; Zagouri, Flora.

Afiliação

Aravantinou-Fatorou A; First Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens 11527, Greece.
Andrikopoulou A; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece.
Liontos M; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece.
Fiste O; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece.
Georgakopoulou VE; First Department of Medicine, National and Kapodistrian University of Athens, School of Medicine, Laiko General Hospital, Athens 11527, Greece.
Dimopoulos MA; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece.
Gavriatopoulou M; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece.
Zagouri F; Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens 11528, Greece.

Oncol Lett ; 22(6): 821, 2021 Dec.

Article em En | MEDLINE | ID: mdl-34691248